ReShape Lifesciences Q1 2023 revenue down 6.3% to $2.3M; operating expenses cut 42.9% YoY

Vyome Holdings, Inc

2023-Q1 EPS reported -$1.56 revenue$2,287,000

Revenue $2.3M (down 6.3% YoY); gross margin improved to 53.5% from 49.9%.
Sales & marketing expenses fell 53.5% to $2.2M; R&D down 39.2% to $0.5M.
Cash $9.1M at March 31, 2023; no debt; expects runway into 2024.
Raised $12.7M in 2023 via February public offering ($10.2M) and April direct offering ($2.5M).
Lap-Band 2.0 PMA supplement submission to FDA expected in coming weeks; feedback by year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Vyome Holdings, Inc reported for the three months ended March 31, 2023 results: revenue $2.3 million.

Period: for the three months ended March 31, 2023
Revenue: $2.3 million
Result: reported results

Exact text from the filing

impact revenue for the remainder of 2023 and move ReShape closer to cash flow breakeven.” First Quarter Ended March 31, 2023, Financial and Operating Results Revenue totaled $2.3 million for the three months ended March 31, 2023, which represents a contraction of 6.3%, or $0.2 million compared to the same period in 2022. The primary reason for the decrease is a

View on SEC.gov

Browse all earnings releases →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001558370-23-009981

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.